Journey Medical Corp(DERM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 48.5% | Shs Outstand | 21.7M | Perf Week | -4.98% |
| Market Cap | 0.14B | Forward P/E | 11.21 | EPS next Y | 454% | Insider Trans | - | Shs Float | 14.5M | Perf Month | -22.86% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | -0.02 | Inst Own | 36.2% | Short Float | 20.56% | Perf Quarter | -19.35% |
| Income | -0.01B | P/S | 2.05 | EPS this Y | 73.4% | Inst Trans | -12.53% | Short Ratio | 15.43 | Perf Half Y | -5.7% |
| Sales | 0.07B | P/B | 4.27 | EPS next 5Y | - | ROA | -6.8% | Short Interest | 2.99M | Perf YTD | -35.67% |
| Book/sh | 1.16 | P/C | 5.46 | EPS past 3/5Y | 34.88% - | ROE | -23.77% | 52W High | -48.09% ($9.56) | Perf Year | -38.15% |
| Cash/sh | 0.91 | P/FCF | - | Sales past 3/5Y | -5.66% 6.79% | ROIC | -11.61% | 52W Low | 15.08% ($4.31) | Perf 3Y | 57.96% |
| Dividend Est. | - | EV/EBITDA | 106.79 | EPS Y/Y TTM | 40.71% | Gross Margin | 59.26% | Volatility(W/M) | 6.74% 6.2% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.05 | Sales Y/Y TTM | 20.89% | Oper. Margin | -4.41% | ATR (14) | 0.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | 93.01% | Profit Margin | -8.95% | RSI (14) | 33.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.59 | Sales Q/Q | 23.33% | SMA20 | -12.54% ($5.67) | Beta | 1.13 | Target Price | $13.75 |
| Payout | - | Debt/Eq | 0.8 | Earnings | 2026/8/12 | SMA50 | -25.12% ($6.62) | Rel Volume | 0.95 | Prev Close | $4.97 |
| Employees | 58 | LT Debt/Eq | 0.64 | EPS/Sales Surpr. | 55.56% 0.82% | SMA200 | -25.76% ($6.68) | Avg Volume(3M) | 0.19M | Price | $4.96 |
| IPO | 2021/11/12 | Option/Short | Yes/Yes | Trades | 1094 | Volume | 183,262 | Change | -0.2% |
Journey Medical (DERM) is a commercial-stage specialty pharmaceutical company focused on the sale and marketing of prescription therapeutics for skin conditions. It has secured multiple FDA-approved products across various dermatology areas, including acne, rosacea, and hyperhidrosis, and pursues a niche strategy of targeting dermatology specialists through its specialized sales organization rather than relying on large pharmaceutical companies.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
DERM has a sound balance sheet but weak earning power
Of every $100 in sales, $4.41 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $205. Peers typically go for $197.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be +58.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #53 of 83 in the industry
Based on market cap of $140M.
DERM#53 Journey Medical Corp $140M PER - 
CRDL#54 Cardiol Therapeutics Inc $138M PER - 
OGI#55 Organigram Global Inc $132M PER 2.1 
BGM#56 BGM Group Ltd $120M PER - 
ORGO#57 Organogenesis Holdings Inc $116M PER - 
FAQ
What kind of company is DERM?
DERM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of DERM?
The market cap of DERM is approximately $140M, ranking 4,271 within its sector.
What is the 52-week high and low for DERM?
DERM has recorded a 52-week high of $9.56 and a low of $4.31.
